Anticancer compositions, and methods of making and using the same
The invention relates to a composition (A), obtained by reacting a compound of the general formula (I) M 3-n-p-2pr [RuX 6-n-p-q-2r B n (H 2 O) p (OH) q (O) r ] 2r+1 (I) with a compound of the general formula (II) B′(HX′) S (II).
1. A kit, comprising:
a first receptacle having a therapeutically effective amount of a compound of the formula (I)
M 3-n-p-2pr [RuX 6-n-p-q-2r B n (H 2 O) p (OH) q (O) r ] 2r+1 (I)
wherein
M is an alkali metal cation or ammonia,
B is indazol,
X is a halide, pseudo-halide, HCO 3 − , or RCOO − , in which R is a substituted or unsubstituted C 1 -C 6 -alkyl or C 2 -C 6 -alkenyl or a substituted or unsubstituted aryl,
n=1 or 2,
p, q=0 or 1 or (if r=0.5) 0 or 0.5, and
r=0 or 0.5; and
a second receptacle having a compound of the formula (II)
B′(HX′) S (II)
wherein
B′ is indazol,
X′ is a halide, pseudo-halide, HCO 3 − , or RCOO − , in which R is hydrogen or a substituted or unsubstituted C 1 -C 6 -alkyl or C 2 -C 6 -alkenyl or a substituted or unsubstituted aryl, phosphate, sulphate, acetate, and
s is an integer of at least 1.
2. The kit according to claim 1 , wherein the molar ratio of the compound of the formula (I) to the compound of the formula (II) is less than 1.
3. The kit according to claim 1 , wherein the molar ratio of the compound of the formula (I) to the compound of the formula (II) is from 1:1.1 to 1:10.
4. The kit according to claim 1 , wherein the molar ratio of the compound of the formula (I) to the compound of the formula (II) is from 1:2 to 1:5.
5. The kit according to claim 1 , wherein M is an alkali metal.
6. The kit according to claim 1 , wherein X and X′ are independently chlorine or bromine.
7. A kit, comprising:
a first receptacle having a therapeutically effective amount of the compound sodium trans-[tetrachlorobis(1H-indazol)-ruthenate(III)]; and
a second receptacle having the compound indazolium hydrochloride.
8. The kit according to claim 7 , wherein the molar ratio of the compound sodium trans-[tetrachlorobis(1H-indazol)-ruthenate(III)] to the compound indazolium hydrochloride is less than 1.
9. The kit according to claim 7 , wherein the molar ratio of the compound sodium trans-[tetrachlorobis(1H-indazol)-ruthenate(III)] to the compound indazolium hydrochloride is from 1:1.1 to 1:10.
10. The kit according to claim 7 , wherein the molar ratio of the compound sodium trans-[tetrachlorobis(1H-indazol)-ruthenate(III)] to the compound indazolium hydrochloride is from 1:2 to 1:5.
11. The kit according to claim 7 , wherein the molar ratio of the compound sodium trans-[tetrachlorobis(1H-indazol)-ruthenate(III)] to the compound indazolium hydrochloride is 1:1.1.